Cargando…

Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage

BACKGROUND: One of the causes of Parkinson's disease is mutations in the PARK2 gene. Deletions and duplications of single exons or exon groups account for a large proportion of the gene mutations. Direct detection of these mutations can be used for the diagnosis of Parkinson's disease. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Shadrina, Maria I, Semenova, Elena V, Slominsky, Petr A, Bagyeva, Gulbahar H, Illarioshkin, Sergei N, Ivanova-Smolenskaia, Irina I, Limborska, Svetlana A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1810516/
https://www.ncbi.nlm.nih.gov/pubmed/17324265
http://dx.doi.org/10.1186/1471-2350-8-6
_version_ 1782132589374472192
author Shadrina, Maria I
Semenova, Elena V
Slominsky, Petr A
Bagyeva, Gulbahar H
Illarioshkin, Sergei N
Ivanova-Smolenskaia, Irina I
Limborska, Svetlana A
author_facet Shadrina, Maria I
Semenova, Elena V
Slominsky, Petr A
Bagyeva, Gulbahar H
Illarioshkin, Sergei N
Ivanova-Smolenskaia, Irina I
Limborska, Svetlana A
author_sort Shadrina, Maria I
collection PubMed
description BACKGROUND: One of the causes of Parkinson's disease is mutations in the PARK2 gene. Deletions and duplications of single exons or exon groups account for a large proportion of the gene mutations. Direct detection of these mutations can be used for the diagnosis of Parkinson's disease. METHODS: To detect these mutations, we developed an effective technique based on the real-time TaqMan PCR system, which allows us to evaluate the copynumbers of the PARK2 gene exons by comparing the intensity of the amplification signals from some exon of this gene with that of the β-globin gene (the internal control). RESULTS: We analyzed rearrangements in exons 1–12 of the PARK2 gene in 64 patients from Russia with early-onset Parkinson's disease. The frequency of these mutations in our patients was 14%. CONCLUSION: We have developed a simple, accurate, and reproducible method applicable to the rapid detection of exon rearrangements in the PARK2 gene. It is suitable for the analysis of large patient groups, and it may become the basis for a diagnostic test.
format Text
id pubmed-1810516
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18105162007-03-07 Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage Shadrina, Maria I Semenova, Elena V Slominsky, Petr A Bagyeva, Gulbahar H Illarioshkin, Sergei N Ivanova-Smolenskaia, Irina I Limborska, Svetlana A BMC Med Genet Research Article BACKGROUND: One of the causes of Parkinson's disease is mutations in the PARK2 gene. Deletions and duplications of single exons or exon groups account for a large proportion of the gene mutations. Direct detection of these mutations can be used for the diagnosis of Parkinson's disease. METHODS: To detect these mutations, we developed an effective technique based on the real-time TaqMan PCR system, which allows us to evaluate the copynumbers of the PARK2 gene exons by comparing the intensity of the amplification signals from some exon of this gene with that of the β-globin gene (the internal control). RESULTS: We analyzed rearrangements in exons 1–12 of the PARK2 gene in 64 patients from Russia with early-onset Parkinson's disease. The frequency of these mutations in our patients was 14%. CONCLUSION: We have developed a simple, accurate, and reproducible method applicable to the rapid detection of exon rearrangements in the PARK2 gene. It is suitable for the analysis of large patient groups, and it may become the basis for a diagnostic test. BioMed Central 2007-02-26 /pmc/articles/PMC1810516/ /pubmed/17324265 http://dx.doi.org/10.1186/1471-2350-8-6 Text en Copyright © 2007 Shadrina et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shadrina, Maria I
Semenova, Elena V
Slominsky, Petr A
Bagyeva, Gulbahar H
Illarioshkin, Sergei N
Ivanova-Smolenskaia, Irina I
Limborska, Svetlana A
Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage
title Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage
title_full Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage
title_fullStr Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage
title_full_unstemmed Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage
title_short Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1–12 dosage
title_sort effective quantitative real-time polymerase chain reaction analysis of the parkin gene (park2) exon 1–12 dosage
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1810516/
https://www.ncbi.nlm.nih.gov/pubmed/17324265
http://dx.doi.org/10.1186/1471-2350-8-6
work_keys_str_mv AT shadrinamariai effectivequantitativerealtimepolymerasechainreactionanalysisoftheparkingenepark2exon112dosage
AT semenovaelenav effectivequantitativerealtimepolymerasechainreactionanalysisoftheparkingenepark2exon112dosage
AT slominskypetra effectivequantitativerealtimepolymerasechainreactionanalysisoftheparkingenepark2exon112dosage
AT bagyevagulbaharh effectivequantitativerealtimepolymerasechainreactionanalysisoftheparkingenepark2exon112dosage
AT illarioshkinsergein effectivequantitativerealtimepolymerasechainreactionanalysisoftheparkingenepark2exon112dosage
AT ivanovasmolenskaiairinai effectivequantitativerealtimepolymerasechainreactionanalysisoftheparkingenepark2exon112dosage
AT limborskasvetlanaa effectivequantitativerealtimepolymerasechainreactionanalysisoftheparkingenepark2exon112dosage